99% success for riboflavin eye procedure

9 March 2009

A US eye specialist says he has developed a nutrient-based surgical  procedure that offers 99% success in the treatment of keratoconus, an  often devastating condition that can lead to blindness.

Brian Boxer Wachler, a world-renowned surgeon and the director of an  eye-care center in Beverly Hills, California, says that C3-R (corneal  collagen cross-linking with riboflavin) is the first vision correction  procedure to use vitamin treatments for the disorder.

A single treatment of C3-R completely halts the disease in its tracks in  99% of cases, according to studies done by Dr Boxer Wachler and other  doctors in Europe. The recovery time is only one day, and patients can  normally resume 100% of their usual activities by the next day. After  five years of study, there have been no side effects reported from this  non-invasive procedure, he noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight